Multivariable analysis for main outcomes measured in each transplant group: unrelated bone marrow (UBMT), T-cell–depleted unrelated bone marrow (T-UBMT), and unrelated cord blood transplants (UCBT) for early and long term outcomes
| . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . | |||
|---|---|---|---|---|---|---|
| Model . | HR (95% CI);P value . | Model . | HR (95% CI); Pvalue . | Model . | HR (95% CI); P value . | |
| Early outcomes7-150 | ||||||
| Neutrophils recovery | Age < 6 years | 1.50 (1.15-2.00); .003 | Cell dose ≥ 3.7 × 108/kg | 1.42 (1.015-2.00); .04 | Cell dose ≥ 0.37 × 108/kg | 1.65 (1.03-2.66), .04 |
| HLA compatibility | 1.39 (0.99-1.96); .06 | |||||
| Platelets recovery | Good risk | 1.61 (1.20-2.17); .002 | Cell dose ≥ 3.7 × | 2.03 (1.41-295); .001 | Cell dose ≥ 0.37 × | 2.29 (1.28-4.11); .006 |
| ↓ weight | 1.01 (1.01-1.02); .009 | 108/kg | 108/kg | |||
| Acute GVHD | — | — | Cell dose < 3.7 × 108/kg | 2.12 (1.03-4.34); .04 | — | — |
| Positive recipient CMV serology | 2.23 (1.102-4.525); .03 | |||||
| Relapse during the first 100 days | Positive recipient CMV serology | 2.88 (1.18-7.05); .02 | — | — | AML | 4.10 (1.1-15.87); .04 |
| Poor risk | 3.15 (0.95-10.43); .06 | |||||
| Poor risk | 2.66 (1.14-6.21); .02 | Age > 6 years | 7.75 (0.98-50); .05 | |||
| Gender (D/R) match | 2.87 (1.17-7.01); .02 | |||||
| TRM | ↑weight | 1.02 (1.00-1.03); .05 | HLA incompatibility | 2.86 (1.23-6.67); .01 | — | — |
| Positive recipient CMV serology | 1.74 (0.97-3.10); .06 | Gender (D/R) match | 4.34 (1.61-11.75); .004 | |||
| Long-term outcomes7-151 | ||||||
| Relapse after day 1007-152 | ABO incompatibility | 1.73 (1.11-2.94); .03 | WBC at diagnosis ≥ 50 G/L | 1.87 (1.08-3.23); .03 | ↓weight | 1.08 (1.04-1.14); .003 |
| Poor risk | 2.18 (1.37-3.45); .001 | Poor risk | 2.74 (1.52-4.93); .0007 | Poor risk | 2.98 (1.27-7); .012 | |
| Positive recipient CMV serology | 1.79 (1.13-2.83); .03 | HLA incompatibility | 1.60 (1.07-2.39); .02 | |||
| Death after day 100 | Poor risk | 1.93 (1.22-3.05); .005 | Poor risk | 2.28 (1.32-3.92); .003 | Poor risk | 3.23 (1.3-7.8); .009 |
| Positive recipient CMV serology | 1.72 (1.08-2.74); .02 | HLA incompatibility | 1.81 (1.21-2.69); .004 | |||
| ↑weight | 1.02 (1.01-1.03); .002 | |||||
| Chronic GVHD7-153 | ↑ weight | 1.02 (1.00-1.03); .006 | — | — | — | — |
| . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . | |||
|---|---|---|---|---|---|---|
| Model . | HR (95% CI);P value . | Model . | HR (95% CI); Pvalue . | Model . | HR (95% CI); P value . | |
| Early outcomes7-150 | ||||||
| Neutrophils recovery | Age < 6 years | 1.50 (1.15-2.00); .003 | Cell dose ≥ 3.7 × 108/kg | 1.42 (1.015-2.00); .04 | Cell dose ≥ 0.37 × 108/kg | 1.65 (1.03-2.66), .04 |
| HLA compatibility | 1.39 (0.99-1.96); .06 | |||||
| Platelets recovery | Good risk | 1.61 (1.20-2.17); .002 | Cell dose ≥ 3.7 × | 2.03 (1.41-295); .001 | Cell dose ≥ 0.37 × | 2.29 (1.28-4.11); .006 |
| ↓ weight | 1.01 (1.01-1.02); .009 | 108/kg | 108/kg | |||
| Acute GVHD | — | — | Cell dose < 3.7 × 108/kg | 2.12 (1.03-4.34); .04 | — | — |
| Positive recipient CMV serology | 2.23 (1.102-4.525); .03 | |||||
| Relapse during the first 100 days | Positive recipient CMV serology | 2.88 (1.18-7.05); .02 | — | — | AML | 4.10 (1.1-15.87); .04 |
| Poor risk | 3.15 (0.95-10.43); .06 | |||||
| Poor risk | 2.66 (1.14-6.21); .02 | Age > 6 years | 7.75 (0.98-50); .05 | |||
| Gender (D/R) match | 2.87 (1.17-7.01); .02 | |||||
| TRM | ↑weight | 1.02 (1.00-1.03); .05 | HLA incompatibility | 2.86 (1.23-6.67); .01 | — | — |
| Positive recipient CMV serology | 1.74 (0.97-3.10); .06 | Gender (D/R) match | 4.34 (1.61-11.75); .004 | |||
| Long-term outcomes7-151 | ||||||
| Relapse after day 1007-152 | ABO incompatibility | 1.73 (1.11-2.94); .03 | WBC at diagnosis ≥ 50 G/L | 1.87 (1.08-3.23); .03 | ↓weight | 1.08 (1.04-1.14); .003 |
| Poor risk | 2.18 (1.37-3.45); .001 | Poor risk | 2.74 (1.52-4.93); .0007 | Poor risk | 2.98 (1.27-7); .012 | |
| Positive recipient CMV serology | 1.79 (1.13-2.83); .03 | HLA incompatibility | 1.60 (1.07-2.39); .02 | |||
| Death after day 100 | Poor risk | 1.93 (1.22-3.05); .005 | Poor risk | 2.28 (1.32-3.92); .003 | Poor risk | 3.23 (1.3-7.8); .009 |
| Positive recipient CMV serology | 1.72 (1.08-2.74); .02 | HLA incompatibility | 1.81 (1.21-2.69); .004 | |||
| ↑weight | 1.02 (1.01-1.03); .002 | |||||
| Chronic GVHD7-153 | ↑ weight | 1.02 (1.00-1.03); .006 | — | — | — | — |
Early outcomes: events occurring during the first 100 days after transplantation.
Long-term outcomes in patients surviving at day 100 posttransplant.
Patients alive and free of relapse at day 100.
Patients alive with sustained engraftment.
Good risk means patients who received a transplant in first or second complete remission (CR); poor risk means patients who received a transplant in relapse or primary refractoriness to chemotherapy or after second CR. CMV indicates human cytomegalovirus; AML, acute myeloid leukemia; WBC, white blood cells; ↑, increasing weight (continuous variable); ↓, decreasing weight (continuous variable).